凝血因子VII 通过阻断AKT-CD36介导脂肪酸摄入来微调肝硬化
Yao Zhang1, Quanxin Jiang1, Xingxing Liang2
1Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Diabetes
|February 23, 2024
概括
非酒精性脂肪性肝病 (NAFLD) 涉及肝脏 VII 凝血因子 (FVII) 的降低. 恢复FVII水平减轻了肝脏脂肪的积累,并显示了NAFLD和NASH的治疗潜力.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 非酒精性脂肪肝 (NAFLD) 与由于凝血障碍引起的心血管问题有关.
- 凝血因子在NAFLD病原体中的特定作用尚未完全理解.
研究的目的:
- 调查结血因子VII (FVII) 在NAFLD中的作用及其潜在机制.
- 探索FVII作为NAFLD/非酒精性脂肪肝炎 (NASH) 的潜在治疗点.
主要方法:
- 在NAFLD/NASH患者和小鼠模型中进行生物信息学分析和功能测试.
- 利用腺病毒介导的F7淘汰和肝细胞特异的F7淘汰小鼠模型.
- 研究了AKT-CD36通路和蛋白质相互作用 (FVII,AKT,PP2A).
主要成果:
- 肝脏FVII表达在NAFLD/NASH中下降.
- 通过AKT-CD36通路抑制脂肪酸吸收,FVII具有非凝固功能,可以减少肝脏脂质的积累.
- 在NAFLD小鼠中,过度表达FVII改善了肝脏肥胖症,炎症,损伤和纤维化.
结论:
- 凝血因子FVII在调节肝硬化症方面发挥着至关重要的作用.
- 在治疗NAFLD和NASH方面,FVII是一个有前途的治疗标.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Extrinsic and Intrinsic Pathways of Hemostasis
7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K


